Developer of a treatment therapy designed to treat Niemann-Pick Type C. The company's treatment therapy uses combination of three drugs which help to treat lysosomal storage diseases, enabling patients to recover severe liver disease from infiltration of the liver and respiratory failure from infiltration of the lungs.
Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
---|---|---|---|---|---|---|
2. Out of Business | 01-Jun-2017 | 00000 | Completed | Out of Business | ||
1. Angel (individual) | 01-Apr-2016 | 00000 | 00000 | Completed | Startup |
Name | Title | Board Seat | Contact Info |
---|---|---|---|
Kasturi Haldar Ph.D | Chief Scientific Officer | ||
William Claypool MD | President, Board Member & Chief Executive Officer | ||
Dennis Willson | Chairman |
Name | Representing | Role | Since |
---|---|---|---|
Dennis Willson | Self | Chairman | 000 0000 |